Ardelyx (ARDX) Projected to Post Earnings on Tuesday

Posted by Brenda Bartman on Oct 27th, 2026

Ardelyx (NASDAQ:ARDX – Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Ardelyx to post earnings of ($0.0148) per share and revenue of $128.66 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Ardelyx (NASDAQ:ARDX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%. The firm had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. The firm’s quarterly revenue was up 34.3% compared to the same quarter last year. On average, analysts expect Ardelyx to post ($0.20) EPS for the current fiscal year and $0.24 EPS for the next fiscal year.

Ardelyx Trading Down 2.6%

ARDX stock opened at $3.00 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. Ardelyx has a twelve month low of $2.99 and a twelve month high of $8.40. The stock has a market capitalization of $747.56 million, a price-to-earnings ratio of -13.64 and a beta of 0.68. The firm’s fifty day simple moving average is $3.52 and its two-hundred day simple moving average is $5.42.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a report on Friday, August 7th. Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Ardelyx in a report on Tuesday, August 18th. Zacks Research upgraded shares of Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. TD Cowen reduced their price objective on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Citigroup decreased their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ardelyx presently has an average rating of “Moderate Buy” and an average target price of $13.90.

Check Out Our Latest Analysis on Ardelyx

Insider Activity at Ardelyx

In other Ardelyx news, insider James Brady sold 15,136 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $58,424.96. Following the transaction, the insider owned 245,930 shares of the company’s stock, valued at $949,289.80. This represents a 5.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael Raab sold 58,574 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $226,095.64. Following the completion of the sale, the chief executive officer owned 1,619,792 shares in the company, valued at approximately $6,252,397.12. The trade was a 3.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,059 shares of company stock worth $486,588 over the last quarter. 5.30% of the stock is owned by insiders.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

Neutral Sentiment: A market-data update reported October short interest of 0 shares and a days-to-cover ratio of 0.0 based on average daily volume. The figure appears inconsistent with the report’s statement that short interest increased, so it provides no clear evidence of meaningful short-selling pressure.
Negative Sentiment: Multiple law firms, including Robbins LLP, Levi & Korsinsky, Bronstein, Kaplan Fox, Rosen Law Firm and Faruqi & Faruqi, reminded investors about a pending securities class action against Ardelyx. The case covers investors who purchased shares between January 13, 2025, and August 6, 2026, with a November 16, 2026 deadline to seek lead-plaintiff status. Robbins LLP class-action announcement
Negative Sentiment: The lawsuit alleges that Ardelyx’s chief executive, two successive chief financial officers and chief commercial officer made or controlled misleading statements regarding projected combined peak sales of $1.75 billion for IBSRELA and XPHOZAH, while payer-access barriers were allegedly developing. These are allegations, not proven findings, but the litigation creates legal, financial and reputational risks for the company. Levi & Korsinsky class-action announcement

Ardelyx Company Profile

(Get Free Report)

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.